Verition Fund Management LLC Purchases New Shares in UroGen Pharma Ltd. (NASDAQ:URGN)

Verition Fund Management LLC acquired a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 13,254 shares of the company’s stock, valued at approximately $168,000. Verition Fund Management LLC owned 0.06% of UroGen Pharma at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Marshall Wace LLP bought a new stake in shares of UroGen Pharma during the 2nd quarter valued at $719,000. Millennium Management LLC lifted its position in UroGen Pharma by 2,672.0% during the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock worth $19,480,000 after purchasing an additional 1,119,019 shares during the period. Point72 Asset Management L.P. grew its stake in UroGen Pharma by 120.3% during the second quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after buying an additional 1,337,257 shares in the last quarter. Wesbanco Bank Inc. bought a new position in UroGen Pharma in the 3rd quarter valued at about $945,000. Finally, Cowen AND Company LLC raised its position in shares of UroGen Pharma by 29.1% in the 2nd quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company’s stock valued at $35,229,000 after buying an additional 472,893 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Stock Down 0.4 %

Shares of NASDAQ URGN opened at $11.30 on Tuesday. The company has a 50 day simple moving average of $12.17 and a 200 day simple moving average of $13.90. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma Ltd. has a 1 year low of $10.60 and a 1 year high of $20.70. The firm has a market cap of $265.03 million, a PE ratio of -3.59 and a beta of 1.06.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same period in the prior year, the firm earned ($0.68) EPS. On average, research analysts forecast that UroGen Pharma Ltd. will post -3.1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on URGN shares. Oppenheimer reissued an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. EF Hutton Acquisition Co. I upgraded UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Friday, December 6th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. Finally, Guggenheim initiated coverage on UroGen Pharma in a research note on Thursday, August 22nd. They set a “buy” rating and a $40.00 target price for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $43.70.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.